125例自身免疫性溶血性贫血治疗实践与结局的单中心回顾性分析
单中心回顾性分析125例AIHA患者,糖皮质激素单药为最常用一线方案但持续缓解率仅10.7%,联合利妥昔单抗的ORR为88.0%、持续缓解率60.0%。28.8%患者发生感染,感染组治疗线数显著更高。
要点
- 糖皮质激素单药一线ORR 61.3%,持续缓解率仅10.7%。
- 激素联合利妥昔单抗一线ORR 88.0%,持续缓解率60.0%。
- 感染患者治疗线数显著高于无感染患者(P<0.001)。
核心结论
- AIHA治疗模式高度异质,糖皮质激素单药仍是最常用一线方案但持续缓解能力有限。
- 糖皮质激素联合利妥昔单抗显示较高ORR与持续缓解率。
- 病程中发生感染患者治疗线数显著增加,需重视感染预防与监测。
研究设计与样本
- 单中心回顾性队列研究,纳入2019年7月至2025年2月中国医学科学院血液病医院125例AIHA患者。
主要发现
- 78.2%(97/124)患者病程中接受过糖皮质激素联合利妥昔单抗治疗。
- 75例一线激素单药ORR 61.3%、持续缓解率10.7%;25例一线激素联合利妥昔单抗ORR 88.0%、持续缓解率60.0%。
- 中位治疗线数2(1~4)线,约三分之一患者需三线及以上治疗。
- 27例(21.6%)复发/难治患者接受新型靶向药物探索性用药,治疗线数显著高于未接受者[4(2~12)对2(1~6),P<0.001],治疗后44.4%缓解、40.7% HGB恢复正常。
- 8例(6.4%)发生静脉血栓事件,36例(28.8%)发生感染,感染组治疗线数显著高于无感染组(P<0.001)。
临床怎么用
- 一线治疗需权衡激素单药持续缓解有限与联合利妥昔单抗较高缓解率。
- 复发/难治患者可考虑新型靶向药物探索性治疗。
- 临床实践中应重视感染预防与监测,尤其多线治疗患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinical characteristics, treatment patterns, and outcomes of patients with autoimmune hemolytic anemia (AIHA) in a single-center retrospective cohort. Methods: Clinical data of 125 patients with AIHA admitted to the Blood Diseases Hospital, Chinese Academy of Medical Sciences, between July 2019 and February 2025, were retrospectively analyzed to investigate their clinical characteristics, treatment patterns, and outcomes. Results: Glucocorticoid monotherapy was the most commonly administered first-line treatment, whereas 78.2% of the patients received glucocorticoids in combination with rituximab during the disease course. The overall response rate (ORR) and the sustained remission rate were 61.3% and 10.7% in 75 patients receiving glucocorticoid monotherapy as first-line treatment and 88.0% and 60.0% in 25 patients treated with glucocorticoids plus rituximab, respectively. The median number of treatment lines was two, with approximately one-third of the patients requiring three or more lines of therapy. In the context of clinical research, 27 (21.6%) patients with relapsed/refractory disease received exploratory treatment with novel targeted agents, with a significantly higher median number of treatment lines compared with those who did not [4 (2-12) vs 2 (1-6), P<0.001]. After treatment, 44.4% of patients achieved remission, whereas 40.7% of patients had their HGB levels normalized. Regarding complications, venous thromboembolism occurred in 8 patients (6.4%). Further, 36 patients (28.8%) developed infections, with a significantly higher number of treatment lines in the infection group than in the noninfection group (P<0.001) . Conclusion: The therapeutic approaches for AIHA demonstrate remarkable heterogeneity. Glucocorticoid monotherapy remains the most commonly administered first-line treatment; however, its ability to maintain sustained remission is limited. Glucocorticoid treatment in combination with rituximab demonstrated a higher ORR and sustained remission rate. Patients who developed infections during the disease course required significantly more lines of therapy, emphasizing the importance of infection prevention and surveillance in clinical practice. 目的: 探索单中心回顾性队列中自身免疫性溶血性贫血(AIHA)患者临床特征、治疗模式及结局。 方法: 回顾性分析2019年7月至2025年2月中国医学科学院血液病医院(中国医学科学院血液学研究所)收治的125例AIHA患者的临床资料,分析其临床特征、治疗模式及结局。 结果: 糖皮质激素单药是最常用的一线治疗方案,而78.2%(97/124)的患者在病程中接受过糖皮质激素联合利妥昔单抗治疗。75例患者接受一线糖皮质激素单药治疗,总体反应率(ORR)为61.3%,持续缓解率仅10.7%;25例接受一线糖皮质激素联合利妥昔单抗治疗,ORR为88.0%,持续缓解率为60.0%。中位治疗线数为2(1~4)线,约三分之一患者需接受三线及以上治疗。27例(21.6%)复发/难治患者在临床研究背景下接受新型靶向药物探索性用药,其治疗线数显著高于未接受者[4(2~12)线对2(1~6)线,P<0.001],治疗后44.4%实现缓解,40.7% HGB恢复正常。并发症方面,8例(6.4%)发生静脉血栓事件,36例(28.8%)发生感染,发生感染患者治疗线数显著高于无感染患者(P<0.001)。 结论: AIHA治疗模式上具有高度异质性,糖皮质激素单药仍是最常用的一线治疗方案,但持续缓解能力有限。糖皮质激素联合利妥昔单抗治疗显示较高的ORR与持续缓解率。病程中发生感染患者治疗线数显著增加,提示临床实践中需重视感染的预防与监测。.
引用
- Yang F, Li RN, Zhang LL, et al. [Treatment practice and outcomes in 125 patients with autoimmune hemolytic anemia: a single-center retrospective analysis]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 41991308. doi:10.3760/cma.j.cn121090-20251209-00582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。